Eleonora Nicolò, MD
@eleonoranicolo.bsky.social
Medical Oncologist, Research Fellow - WeillCornellMedicine & CristofanilliLab
Focus: Breast Cancer, Liquid Biopsy, Translational Research
Focus: Breast Cancer, Liquid Biopsy, Translational Research
Reposted by Eleonora Nicolò, MD
🧵 Thread — Clinical opportunities of circulating tumor cells (CTCs) in breast cancer.
CTCs = validated prognostic marker in MBC:
🏎️ ≥5 CTCs/7.5 mL → stage IVaggressive
🚲 <5 CTCs/7.5 mL → stage IVindolent
Our takeaway 👉 www.thebreastonline.com/article/S096...
#CTCs #BreastCancer
CTCs = validated prognostic marker in MBC:
🏎️ ≥5 CTCs/7.5 mL → stage IVaggressive
🚲 <5 CTCs/7.5 mL → stage IVindolent
Our takeaway 👉 www.thebreastonline.com/article/S096...
#CTCs #BreastCancer
Mapping Breast Cancer Therapy with Circulating Tumor Cells: the expert perspective
Circulating tumor cells (CTCs) have emerged as a key prognostic biomarker for breast
cancer, with their role becoming more pronounced in metastatic cases. In metastatic
breast cancer, having five or m...
www.thebreastonline.com
April 5, 2025 at 6:51 PM
🧵 Thread — Clinical opportunities of circulating tumor cells (CTCs) in breast cancer.
CTCs = validated prognostic marker in MBC:
🏎️ ≥5 CTCs/7.5 mL → stage IVaggressive
🚲 <5 CTCs/7.5 mL → stage IVindolent
Our takeaway 👉 www.thebreastonline.com/article/S096...
#CTCs #BreastCancer
CTCs = validated prognostic marker in MBC:
🏎️ ≥5 CTCs/7.5 mL → stage IVaggressive
🚲 <5 CTCs/7.5 mL → stage IVindolent
Our takeaway 👉 www.thebreastonline.com/article/S096...
#CTCs #BreastCancer
Liquid biopsy to advance precision oncology for patients with breast cancer ➡️ highlights from SABCS 2024 📢
Check our editorial here: www.sciencedirect.com/science/arti...
Check our editorial here: www.sciencedirect.com/science/arti...
January 12, 2025 at 8:45 PM
Liquid biopsy to advance precision oncology for patients with breast cancer ➡️ highlights from SABCS 2024 📢
Check our editorial here: www.sciencedirect.com/science/arti...
Check our editorial here: www.sciencedirect.com/science/arti...
Reposted by Eleonora Nicolò, MD
The BRIDGES study @JCO GO
❓ Management of IBC in low and middle income countries
✅ 112 responses from clinicians from 36 counties
🔑 1/3 of patients with non metastatic IBC are receiving TMT
🔑 provider education everywhere is key to improve patient outcomes
ascopubs.org/doi/pdf/10.1...
❓ Management of IBC in low and middle income countries
✅ 112 responses from clinicians from 36 counties
🔑 1/3 of patients with non metastatic IBC are receiving TMT
🔑 provider education everywhere is key to improve patient outcomes
ascopubs.org/doi/pdf/10.1...
December 20, 2024 at 9:12 PM
The BRIDGES study @JCO GO
❓ Management of IBC in low and middle income countries
✅ 112 responses from clinicians from 36 counties
🔑 1/3 of patients with non metastatic IBC are receiving TMT
🔑 provider education everywhere is key to improve patient outcomes
ascopubs.org/doi/pdf/10.1...
❓ Management of IBC in low and middle income countries
✅ 112 responses from clinicians from 36 counties
🔑 1/3 of patients with non metastatic IBC are receiving TMT
🔑 provider education everywhere is key to improve patient outcomes
ascopubs.org/doi/pdf/10.1...
Reposted by Eleonora Nicolò, MD
CDK4/6 inhibitors: mechanisms of resistance and where to find them.
An outside of the box review
Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear
Read more👇
www.sciencedirect.com/science/arti...
#bcsm #BreastCancer
An outside of the box review
Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear
Read more👇
www.sciencedirect.com/science/arti...
#bcsm #BreastCancer
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): mechanisms of resistance and where to find them
CDK4/6 inhibitors (CDK4/6i) have significantly impacted on the treatment of HR+ HER2 negative (HER2-) metastatic breast cancer (BC) when combined with…
www.sciencedirect.com
December 20, 2024 at 7:50 AM
CDK4/6 inhibitors: mechanisms of resistance and where to find them.
An outside of the box review
Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear
Read more👇
www.sciencedirect.com/science/arti...
#bcsm #BreastCancer
An outside of the box review
Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear
Read more👇
www.sciencedirect.com/science/arti...
#bcsm #BreastCancer
📢 Happy to share our last paper on the role of germline BRCA mut in PARPi-related hematologic AEs
⚠️ No differences between carriers vs. non-carriers
⚠️ No differences between carriers vs. non-carriers
December 2, 2024 at 11:25 PM
📢 Happy to share our last paper on the role of germline BRCA mut in PARPi-related hematologic AEs
⚠️ No differences between carriers vs. non-carriers
⚠️ No differences between carriers vs. non-carriers